114th Day Of Lockdown

Maharashtra27564015261310928 Tamil Nadu1518201023102167 Delhi116993956993487 Karnataka4725318467933 Gujarat44648313462080 Uttar Pradesh41383257431012 Telangana3934225999386 Andhra Pradesh3545118378452 West Bengal34427206801000 Rajasthan2643719502530 Haryana2330617667319 Bihar2017313533157 Assam197551288953 Madhya Pradesh1964313908682 Odisha1489810476101 Jammu and Kashmir116666337206 Kerala9554463436 Punjab87995867221 Jharkhand4562248538 Chhatisgarh4556332420 Uttarakhand3785294850 Goa2951167418 Tripura228116043 Manipur170010800 Puducherry159688921 Himachal Pradesh134196610 Nagaland9023480 Chandigarh61945911 Arunachal Pradesh4911533 Meghalaya337462 Mizoram2381590 Sikkim222870
World Europe 06 Jun 2020 British scientists h ...

British scientists halt hydroxychloroquine trial, call it 'useless'

REUTERS
Published Jun 6, 2020, 3:34 pm IST
Updated Jun 6, 2020, 5:41 pm IST
The malaria drug was touted by U.S. President Donald Trump as a potential 'game changer' in the pandemic
A bottle and pills of Hydroxychloroquine. (AFP)
 A bottle and pills of Hydroxychloroquine. (AFP)

London: British scientists halted a major drug trial on Friday after it found that the anti-malarial hydroxychloroquine, touted by U.S. President Donald Trump as a potential “game changer” in the pandemic, was “useless” at treating COVID-19 patients.

“This is not a treatment for COVID-19. It doesn’t work,” Martin Landray, an Oxford University professor who is co-leading the RECOVERY trial, told reporters.

 

“This result should change medical practice worldwide. We can now stop using a drug that is useless.”

Vocal support from Trump raised expectations for the decades-old drug that experts said could have been a cheap and widely available tool, if proven to work, in fighting the pandemic, which has infected more than 6.4 million people and killed nearly 400,000 worldwide

Controversy surrounding the drug grew after a study published in medical journal The Lancet last month raised safety concerns and led several COVID-19 studies of it to be halted. The Lancet study was then retracted on Thursday after its authors said they were unsure about its data.

 

Landray, a professor of medicine and epidemiology at Oxford University, noted the “huge speculation” about the drug as a treatment for COVID-19 but said there had been until now “an absence of reliable information from large randomised trials”.

He said the preliminary results from RECOVERY, which was a randomised trial, were now quite clear: hydroxychloroquine does not reduce the risk of death among hospitalised patients with COVID-19.

“If you’re admitted to hospital, don’t take hydroxychloroquine,” he said.

 

The RECOVERY trial of hydroxychloroquine had randomly assigned 1,542 COVID-19 patients to hydroxychloroquine and compared them with 3,132 COVID-19 patients randomly assigned to standard care without the drug.

Results showed no significant difference in death rates after 28 days, in length of stay in hospital or in other outcomes, the researchers said.

The World Health Organization (WHO) said on Wednesday it would resume tests of hydroxychloroquine as part of its ‘Solidarity’ trials, after those running the study briefly stopped giving it to new patients in light of the Lancet paper.

 

Peter Horby, an Oxford University professor who is co-leading the RECOVERY trial with Landray, said his team had informed the WHO of their decision to halt the UK study.

“There was a call this morning with the WHO to give them a heads-up on the results... They... said they would be convening their committee to look again at their decision regarding the Solidarity trial.”

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT